Single-cell RNA sequencing analysis of human bone-marrow-derived mesenchymal stem cells and functional subpopulation identification – DocWire News

This article was originally published here

Exp Mol Med. 2022 Apr 1. doi: 10.1038/s12276-022-00749-5. Online ahead of print.

ABSTRACT

Mesenchymal stem cells (MSCs) are a common kind of multipotent cell in vivo, but their heterogeneity limits their further applications. To identify MSC subpopulations and clarify their relationships, we performed cell mapping of bone-marrow-derived MSCs through single-cell RNA (scRNA) sequencing. In our study, three main subpopulations, namely, the stemness subpopulation, functional subpopulation, and proliferative subpopulation, were identified using marker genes and further bioinformatic analyses. Developmental trajectory analysis showed that the stemness subpopulation was the root and then became either the functional subpopulation or the proliferative subpopulation. The functional subpopulation showed stronger immunoregulatory and osteogenic differentiation abilities but lower proliferation and adipogenic differentiation. MSCs at different passages or isolated from different donors exhibited distinct cell mapping profiles, which accounted for their corresponding different functions. This study provides new insight into the biological features and clinical use of MSCs at the single-cell level, which may contribute to expanding their application in the clinic.

PMID:35365767 | DOI:10.1038/s12276-022-00749-5

See more here:
Single-cell RNA sequencing analysis of human bone-marrow-derived mesenchymal stem cells and functional subpopulation identification - DocWire News

U.S. STEM CELL, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) – Marketscreener.com

The following is management's discussion and analysis ("MD&A") of certainsignificant factors that have affected our financial position and operatingresults during the periods included in the accompanying financial statements, aswell as information relating to the plans of our current management. This reportincludes forward-looking statements. Generally, the words "believes,""anticipates," "may," "will," "should," "expect," "intend," "estimate,""continue," and similar expressions or the negative thereof or comparableterminology are intended to identify forward-looking statements. Such statementsare subject to certain risks and uncertainties, including the matters set forthin this report or other reports or documents we file with the Securities andExchange Commission from time to time, which could cause actual results oroutcomes to differ materially from those projected. Undue reliance should not beplaced on these forward-looking statements which speak only as of the datehereof. We undertake no obligation to update these forward-looking statements.

The following discussion and analysis should be read in conjunction with our financial statements and the related notes thereto and other financial information contained elsewhere in this Form 10-K

Our Ability To Continue as a Going Concern

--------------------------------------------------------------------------------

Index

Biotechnology Product Candidates

GENERAL AMERICAN CAPITAL PARTNERS

--------------------------------------------------------------------------------

Index

Results of Operations Overview

Comparison of Years Ended December 31, 2021 and December 31, 2020

Cost of sales consists of the costs associated with the production of MyoCath and test kits, product costs, labor for production and training and lab and banking costs consistent with products and services provided.

Cost of sales was $52,030 in the year ended December 31, 2021 compared to $64,117 in the year ended December 31, 2020. The decrease is due to the decrease in revenues.

Research and development expenses were $0 in 2021 remaining the same as $0 in 2020.

Selling, General and Administrative

Gain (loss) on settlement of debt

--------------------------------------------------------------------------------

In valuing our common stock, our Board of Directors considered a number of factors, including, but not limited to:

--------------------------------------------------------------------------------

Index

Options outstanding at December 31, 2021 110,643,884 $ 0.0247

Options exercisable at December 31, 2021 93,491,384 $ 0.0256

Available for grant at December 31, 2021 34,168,070

Average Number Weighted Average

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Index

Our primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments, laboratory services and cell banking.

Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied.

Research and Development Costs

--------------------------------------------------------------------------------

Depreciation is computed using the straight-line method over the assets' expected useful lives or the term of the lease, for assets under capital leases.

Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less.

We allocate the proceeds received from equity financing and the attached options and warrants issued, based on their relative fair values, at the time of issuance. The amount allocated to the options and warrants is recorded as additional paid in capital.

Selling, General and Administrative

Our opinion is that inflation has not had, and is not expected to have, a material effect on our operations.

Liquidity and Capital Resources

In 2021, we continued to finance our operational cash needs with cash generated from financing activities.

Economic Injury Disaster Loan (EIDL)

--------------------------------------------------------------------------------

Net cash provided by investing activities was $0 for the year ended December 31, 2021.

Existing Capital Resources and Future Capital Requirements

As of December 31, 2021, we had $8,016,314 in outstanding debt, net of debt discount of $273,216.

Off-Balance Sheet Arrangements

Recent Accounting Pronouncements

Refer to Note 1. Organization and Summary of Significant Accounting Policies in the notes to our financial statements for a discussion of recent accounting pronouncements.

Edgar Online, source Glimpses

Follow this link:
U.S. STEM CELL, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) - Marketscreener.com

IMAC Holdings Reports Preliminary Fourth Quarter and Year End 2021 Financial Results and … – The Denver Gazette

Revenue increased 26% for quarter and 12% annually

BRENTWOOD, Tenn., March 31, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc.(Nasdaq:IMAC) (IMAC or the Company), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today reported its preliminary financial results for the year endedDecember 31, 2021.

Financial Highlights from Q4 2021:

Financial Highlights from FY 2021(all comparisons are withIMACfor the year endedDecember 31, 2020unless otherwise indicated):

Corporate Highlights in Q4 2021 and Year To Date 2022:

The fourth quarter of 2021 was productive. We started the quarter with the acquisition of Louisiana Orthopaedic and Spine Institute which we expect to be our largest clinic by the second half of 2022. And by the end of the quarter, we delivered 26% revenue growth on a 9.7% increase of patients visits compared to Q4 of 2020, said Jeffrey Ervin, IMACs Chief Executive Officer.

During 2021, we worked diligently to reduce the Companys debt, retiring greater than $4.13 million representing over 90% of notes payable. We are well positioned for strategic growth objectives in 2022 that solidify our foundation as we continue to execute on our strategic initiatives. Today, we filed an extension to accommodate the additional time needed for our former and current auditors to complete our 10k filing.

Another significant accomplishment during 2021 included growing our service footprint with the launch of The Back Space retail chiropractic pilot program in select Walmart locations. We opened 10 stores in three markets as part of the pilot and recently completed The Back Company franchise to expand The Back Space presence. The infrastructure incorporates technical advancements with our consumer engagement tools as evidenced with the launch The Back mobile app, the first in the chiropractic industry to provide mobile queue registration. Dr. Ben Lerner recently joined the team as COO with an emphasis on leading The Back Companys growth using his franchise and high-growth experience after a 17-year tenure as founder and CEO of a large chiropractic franchisor and lifestyle company.

Finally, weve already completed the second cohort and initiated the third cohort of our Phase 1 clinical trial. We anticipate completing our third and final cohort during summer, 2022. Each of these milestones are part of IMAC Holdings roadmap to helping consumers develop a personalized, affordable and engaging experience that guides users to better spinal health and physical function. There was demonstrable progress during 2021 to set up a springboard of growth for 2022.

Results of Operations for the Twelve Months EndedDecember 31, 2021Compared to the Twelve Months EndedDecember 31, 2020

Total revenue increased 12% from 12.8 million in 2020 to $14.4 million in 2021. Total revenues increased $1.6 million due to a combination of acquisitions, same-store growth, and the opening of retail chiropractic clinics. The increase in operating expenses from$19.4 million in 2020 to $24.5 million in 2021 was driven by a combination of additional salaries and expenses related to acquisitions and The Back Space launch in 2021 as well as the $0.42 million reduction in expenses from grant funds in 2020, resulting in an increase in operating loss to$10.1 million versus a loss of $6.5 millionin 2020.

For the year endedDecember 31, 2021, the Company reported cash and cash equivalents of$7.1 million, compared with approximately$2.6 millionas ofDecember 31, 2020.

AboutIMAC Holdings, Inc.

IMAC Holdingsowns and manages health and wellness centers that deliver sports medicine, orthopedic, and life science therapies for movement restricting diseases.IMACis comprised of three business segments: outpatient medical centers, The Back Space, and a clinical research division. With treatments to address the aging population,IMAC Holdingsowns or manages more than 15 outpatient medical clinics and has partnered with several active and former professional athletes, includingOzzie Smith,David Price,Mike Ditka, andTony Delkto promote a minimally invasive approach to sports medicine. IMACs The Back Space retail spine health and wellness treatment centers deliver chiropractic care within Walmart locations. IMACs research division is currently conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinsons disease. For more information visit http://www.imacholdings.com.

###

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as anticipate, expect, believe, may, will, should or other comparable terms, are based largely onIMAC'sexpectations and are subject to a number of risks and uncertainties, certain of which are beyondIMAC'scontrol. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers requirements, and its ability to protect its intellectual property.IMACencourages you to review other factors that may affect its future results in its registration statement and in its other filings with theSecurities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact:

Laura Fristoe

lfristoe@imacrc.com

Visit link:
IMAC Holdings Reports Preliminary Fourth Quarter and Year End 2021 Financial Results and ... - The Denver Gazette

Learning from the single cell: A new technique to unravel gene regulation – EurekAlert

image:zebrafish notochord nuclei at 15-somite stage. Grey: nuclear DNA (DAPI). Color: histone H3K9me3 view more

Credit: Phong Nguyen, Franka Rang & Kim de Luca. Copryight Hubrecht Institute.

How is the activity of genes regulated by the packaging of DNA? To answer this question, a technique to measure both gene expression and DNA packaging at the same time was developed by Franka Rang and Kim de Luca, researchers from the group of Jop Kind (group leader at the Hubrecht Institute and Oncode Investigator). This method, EpiDamID, determines the location of modified proteins around which the DNA is wrapped. It is important to gather information about these modifications, because they influence the accessibility of DNA, thereby affecting the gene activity. EpiDamID is therefore valuable for research into the early development of organisms. The results of the study are published in Molecular Cell on April 1st 2022.

In order to fit DNA into the nucleus of a cell, it is tightly packed around nuclear proteins: histones. Depending on the tightness of this winding, the DNA can be (in)accessible to other proteins. This therefore determines whether the process of gene expression, translation of DNA into RNA and eventually into proteins, can take place.

DNA packaging determine gene activity

The tightness of DNA winding around histones is regulated by the addition of molecular groups, so-called post-translational modifications (PTMs), to the histones. For example, if certain molecules are added to the histones, the DNA winding is loosened. This makes the DNA more accessible for certain proteins and causes the genes in this part of the DNA to become active, or expressed. Furthermore, proteins that are crucial for gene expression can directly recognize and bind the PTMs. This enables transcription: the process of DNA copying.

The regulation of gene expression, for instance through PTMs, is also known as epigenetic regulation. Since all cells in a body have the same DNA, regulation of gene expression is needed to (de)activate specific functions in individual cells. For instance, heart muscle cells have different functions than skin cells, thus require different genes to be expressed.

Analysis of single cells using EpiDamID

To understand how PTMs affect gene expression, first authors Franka Rang and Kim de Luca designed a new method to determine the location of the modifications. Using this approach, called EpiDamID, researchers can analyze single cells, whereas previous methods were only able to measure a large group of cells. Analysis on such a small scale results in knowledge on how DNA winding differs per cell, rather than information on the average DNA winding of many cells.

EpiDamID is based on DamID, a technique which is used to determine the binding location of certain DNA-binding proteins. Using EpiDamID, the binding location of specific PTMs on histone proteins can be detected in single cells. Compared to others, a great advantage of this technique is that researchers need very limited material. Furthermore, EpiDamID can be used in combination with other methods, such as microscopy, to study regulation of gene expression on different levels.

Future prospects

Following the development of this technique, the Kind group will focus on the role of PTMs from the point of view of developmental biology. Because single cells are analyzed using EpiDamID, only a limited amount of material is needed to generate enough data. This allows researchers to study the early development of organisms from its first cell divisions, when the embryo consists of only a few cells.

###

Publication

Rang, F. J.*, de Luca, K. L.*, de Vries, S. S., Valdes-Quezada, C., Boele, E., Nguyen, P. D., Guerreiro, I., Sato, Y., Kimura, H., Bakkers, J. & Kind, J. Single-cell profiling of transcriptome and histone modifications with EpiDamID. Molecular Cell, 2022.

*Authors contributed equally

Jop Kind is group leader at the Hubrecht Institute for Developmental Biology and Stem Cell Research and Oncode Investigator.

About the Hubrecht Institute

The Hubrecht Institute is a research institute focused on developmental and stem cell biology. It encompasses 21 research groups that perform fundamental and multidisciplinary research, both in healthy systems and disease models. The Hubrecht Institute is a research institute of the Royal Netherlands Academy of Arts and Sciences (KNAW), situated on Utrecht Science Park. Since 2008, the institute is affiliated with the UMC Utrecht, advancing the translation of research to the clinic. The Hubrecht Institute has a partnership with the European Molecular Biology Laboratory (EMBL). For more information, visit http://www.hubrecht.eu.

Experimental study

Cells

Single-cell profiling of transcriptome and histone modifications with EpiDamID

1-Apr-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See the original post here:
Learning from the single cell: A new technique to unravel gene regulation - EurekAlert

Getting a Stem Cell or Bone Marrow Transplant

When the decision is made to have a stem cell or bone marrow transplant, there are several steps in theprocess. The steps are much the same, no matter what type of transplant youre going to have.

You will first be evaluated to find out if you are eligible for a transplant. A transplant is very hard on your body. For many people, transplants can mean a cure, but for some people, problems can lead to severe complications or even death. Youll want to weigh the benefits and risks before you start.

Transplants can also be hard emotionally. They often require being in the hospital, being isolated, and theres a high risk of side effects. Many of the effects are short-term, but some problems can go on for years. This can mean changes in the way you live your life. For some people its just for a while, but for others, the changes may be lifelong. Some of the side effects are really unpleasant and can be serious. Your cancer care team will do everything they can to make you comfortable, but some of the side effects may not be completely controlled or relieved.

Before you have a transplant, you need to discuss the transplant process and all its effects with your doctors. It also helps to talk with others who have already had transplants.

Its also very hard going through weeks and months of not knowing how your transplant will turn out. This takes a lot of time and emotional energy from the patient, caregivers, and loved ones. Its very important to have the support of those close to you. For example, youll need a responsible adult who will be with you to give you medicines, help watch for problems, and stay in touch with your transplant team after you go home. Your transplant team will help you and your caregiver learn what you need to know. The team can also help you and your loved ones work through the ups and downs as you prepare for and go through the transplant.

Many different medical tests will be done, and questions will be asked to try to find out how well you can handle the transplant process. These might include:

You will also talk about your health insurance coverage and related costs that you might have to pay.

You may have a central venous catheter (CVC) put into a large vein in your chest. This is most often done as outpatient surgery, and usually only local anesthesia is needed (the place where the catheter goes in is made numb). Nurses will use the catheter to draw blood and give you medicines.

If youre getting an autologous transplant, a special catheter can be placed that can also be used when your stem cells are being removed or harvested.

The CVC will stay in during your treatment and for some time afterward, usually until your transplanted stem cells have engrafted and your blood counts are on a steady climb to normal.

Younger people, people who are in the early stages of disease, or those who have not already had a lot of treatment, often do better with transplants. Some transplant centers set age limits. Some people also may not be eligible for transplant if they have other major health problems, such as serious heart, lung, liver, or kidney disease. A mini-transplant, described under Allogeneic stem cell transplant in Types of Stem Cell Transplants for Cancer Treatment may be an option for some of these people.

The hospitals transplant team will decide if you need to be in the hospital to have your transplant, if it will be done in an outpatient center, or if you will be in the hospital just for parts of it. If you have to be in the hospital, you will probably go in the day before pre-transplant chemo or radiation treatment begins (see the next section), the transplant team makes sure you and your family understand the process and want to go forward with it.

If you will be having all or part of your transplant as an outpatient, youll need to be very near the transplant center during the early stages. Youll need a family member or loved one to be a caregiver who can stay with you all the time. You and the caregiver will also need reliable transportation to and from the clinic. The transplant team will be watching you closely for complications, so expect to be at the clinic every day for a few weeks. You may still need to be in the hospital if your situation changes or if you start having complications.

To reduce the chance of infection during treatment, patients who are in the hospital are put in private rooms that have special air filters. The room may also have a protective barrier to separate it from other rooms and hallways. Some have an air pressure system that makes sure no unclean outside air gets into the room. If youre going to be treated as an outpatient, you will get instructions on avoiding infection. Usually, people who have transplants are in a separate, special part of the hospital to keep as many germs away as possible.

The transplant experience can be overwhelming. Your transplant team will be there to help you prepare for the process physically and emotionally and to discuss your needs. Every effort will be made to answer questions so you and your family fully understand what will be happening to you as you go through transplant.

Its important for you and your family to know what to expect, because once conditioning treatment begins (see the next section), theres no going back there can be serious problems if treatment is stopped at any time during transplant.

Having a transplant takes a serious commitment from you and your caregiver and family, so it is important to know exactly what to expect.

Conditioning, also known as pre-transplant treatment,bone marrow preparation, or myeloablation, is usually treatment with high-dose chemo and/or radiation therapy. Its the first step in the transplant process and typically takes a week or two. Its done for one or more of these reasons:

The conditioning treatment is different for every transplant. Your treatment will be planned based on the type of cancer you have, the type of transplant, and any chemo or radiation therapy youve had in the past.

If chemo is part of your treatment plan, it will be given in your central venous catheter and/or as pills. If radiation therapy is planned, its given to the entire body (called total body irradiation or TBI). TBI may be given in a single treatment session or in divided doses over a few days.

This phase of the transplant can be very uncomfortable because very high treatment doses are used. Chemo and radiation side effects can make you sick, and it may take you months to fully recover. A very common problem is mouth sores that will need to be treated with strong pain medicines. You may also have nausea, vomiting, be unable to eat, lose your hair, and have lung or breathing problems.

Conditioning can also cause premature menopause in women and often makes people sterile (unable to have children). (See Stem Cell Transplant Side Effects.)

After the conditioning treatment, youll be given a couple of days to rest before getting the stem cells. They will be given through your central venous catheter, much like a blood transfusion. If the stem cells were frozen, you might get some drugs before the stem cells are given. These drugs are used to help reduce your risk of reacting to the preservatives that are used when freezing the cells.

If the stem cells were frozen, they are thawed in warm water then given right away. There may be more than 1 bag of stem cells. For allogeneic or syngeneic transplants, the donor cells may be harvested (removed) in an operating room, and then processed in the lab right away. Once they are ready, the cells are brought in and given to you theyre not frozen. The length of time it takes to get all the stem cells depends on how much fluid the stem cells are in.

You will be awake for this process, and it doesnt hurt. This is a big step and often has great meaning for patientsand their families. Many people consider this their rebirth or chance at a second life. They may celebrate this day as they would their actual birthday.

Side effects from the infusion are rare and usually mild. The preserving agent used when freezing the stem cells causes many of the side effects. For instance, you might have a strong taste of garlic or creamed corn in your mouth. Sucking on candy or sipping flavored drinks during and after the infusion can help with the taste. Your body will also smell like this. The smell may bother those around you, but you might not even notice it. The smell, along with the taste, may last for a few days, but slowly fades away. Often having cut up oranges in the room will offset the odor. Patients who have transplants from cells that were not frozen do not have this problem because the cells are not mixed with the preserving agent.

Other side effects you might have during and right after the stem cell infusion include:

Again, side effects are rare and usually mild. If they do happen, they are treated as needed. The stem cell infusion must always be completed.

The recovery stage begins after the stem cell infusion. During this time, you and your family wait for the cells to engraft, or take, after which they start to multiply and make new blood cells. The time it takes to start seeing a steady return to normal blood counts varies depending on the patient and the transplant type, but its usually about 2 to 6 weeks. Youll be in the hospital or visit the transplant center daily for a number of weeks.

During the first couple of weeks youll have low numbers of red and white blood cells and platelets. Right after transplant, when your counts are the lowest, you may be given antibiotics to help keep you from getting infections. You may get a combination of anti-bacterial, anti-fungal, and anti-viral drugs. These are usually given until your white blood cell count reaches a certain level. Still, you can have problems, such as infection from too few white blood cells (neutropenia), or bleeding from too few platelets (thrombocytopenia). Many patients have high fevers and need IV antibiotics to treat serious infections. Transfusions of red blood cells and platelets are often needed until the bone marrow starts working and new blood cells are being made by the infused stem cells.

Except for graft-versus-host disease, which only happens with allogeneic transplants, the side effects from autologous, allogeneic, and syngeneic stem cell transplants are much the same. Problems may include stomach, heart, lung, liver, or kidney problems. (Stem Cell Transplant Side Effects goes into the details.) You might also go through feelings of distress, anxiety, depression, joy, or anger. Adjusting emotionally after the stem cells can be hard because of the length of time you feel ill and isolated from others.

You might feel as if you are on an emotional roller coaster during this time. Support and encouragement from family, friends, and the transplant team are very important to get you through the challenges after transplant.

The discharge process actually begins weeks before your transplant. It starts with the transplant team teaching you and your primary (main) caregiver about:

For the most part, transplant centers dont send patients home until they meet the following criteria:

(Why Are Stem Cell Transplants Used as Cancer Treatment? has more information about neutrophils, platelets, and hematocrit).

If you do not meet all of these requirements, but still dont need the intensive care of the transplant unit, you might be moved to another oncology unit. When you do go home, you might need to stay near the transplant center for some time, depending on your condition.

The process of stem cell transplant doesnt end when you go home. Youll feel tired, and some people have physical or mental health problems in the rehabilitation period. You might still be taking a lot of medicines. These ongoing needs must now be managed at home, so caregiver and friend/family support is very important.

Transplant patients are followed closely during rehab. You might need daily or weekly exams along with things like blood tests, and maybe other tests, too. During early rehab, you also might need blood and platelet transfusions, antibiotics, or other treatments. At first youll need to see your transplant team often, maybe even every day, but youll progress to less frequent visits if things are going well. It can take 6 to 12 months, or even longer, for blood counts to get close to normal and your immune system to work well. During this time, your team will still be closely watching you.

Some problems might show up as much as a year or more after the stem cells were infused. They can include:

Other problems can also come up, such as:

Your transplant team is still there to help you, even though the transplant happened months ago. Its important that you tell them about any problems you are having they can help you get the support you need to manage the changes that you are going through. They can also help you know if problems are serious, or a normal part of recovery. The National Bone Marrow Transplant Link helps patients, caregivers, and families by providing information and support services before, during, and after transplant. They can be reached at 1-800-LINK-BMT (1-800-546-5268) or online at http://www.nbmtlink.org.

Read the original:
Getting a Stem Cell or Bone Marrow Transplant

What is Stem Cell Research? | The Benefits of Stem Cell …

Stem cell research is one of the most innovative research methods being used in modern society. However, it is also not very well known in todays society. Most people are either introduced to it when exposed to the treatment themselves or through a loved one.I was exposed to stem cell research in the ninth grade. Since I went to a STEM(science, technology, engineering, and mathematics) high school, my biology teacher assigned us a report on stem cell research. Since doing that report, I have become passionate about stem cell research and have followed closely the advancements made in the field. Current research can easily be tracked on the National Institute for Health website.

So what is a stem cell? Astem cell is simply a cell that can either reproduce another stem cell or a specialized cell an infinitive amount of times. The specialized cells that can be produced have specific function related to where they are produced in the human body.Stem cell research is also categorized by the stem cell typeused.

Adult stem cells, or somatic cells, are produced from the human body once an individual is born. It can renew itself or become a specialized cell within the body just like the stem cells I explained above. They have no known origin, but they are used in most of the groundbreaking research that is currently happening.

Embryonic stem cells are more controversial since they are produced in the embryo stage of development. All embryonic stem cells originate from an embryo. They are usually grown in a laboratory within a cell culture. There are many misconceptions of embryonic stem cells which will be addressed in the next blog post.

Both types of stem cells have advantages and disadvantages, but the advantage of stem cell research heavily outweigh the disadvantages. It is slowly becoming the future of medicine.

The rest is here:
What is Stem Cell Research? | The Benefits of Stem Cell ...

Is Stem Cell Therapy Right for You? – Health Essentials from Cleveland Clinic

Few of us know what they are or exactly how they work. But many of us have heard about the healing powers of stem cells, as well as the controversy surrounding them. Stem cells are well-debated and highly complex with promises ranging from fixing damaged knees to regenerating receding hairlines.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

But what are stem cells? And, whats all the fuss all about?

Director of the Center for Regenerative Medicine and Surgery, Amy Lightner, MD, shares the differences between stem cell types, how stem cells can be used and when to be cautious of claims that might be too good to be true.

When most of us think of stem cells, we probably recall images of Dolly the cloned sheep. While its true that Dolly was born of stem cells, her place in science history is just one of many advancements in the field.

In fact, there are many different types of stem cells, each of which has different responsibilities and abilities. What unifies them is their ability to regenerate into new cells.

Regenerative medicine is an emerging field that uses innovative treatments to help regenerate or heal cell function thats lost due to aging, disease or injury, Dr. Lightner explains. The way we achieve this is by using stem cells in large quantities, targeted to a certain area, that the body uses to promote healing.

Adult stem cells are the only type of stem cells that are currently approved for medical use in the United States by the U.S. Food and Drug Administration (FDA). The term adult stem cells is a little confusing because theyre actually found in infants, children and adults. These cells live in a variety of tissue in our bodies including bone marrow, muscles, your brain, your intestines and more.

Think of adult stem cells as a little army of cells that can regenerate themselves into new cells to maintain and repair the tissue or muscle where theyre found. The catch with adult stem cells is that they cant become different types of cells (for example, blood stem cells can only become new blood cells, not skin or brain cells).

Unlike adult stem cells, embryonic stem cells have many more possibilities. Harvested during an embryos blastocyst stage (about five or six days after an embryo has been fertilized in a lab), embryonic stem cells have the potential to become any type of cell (called pluripotent cells). For these reasons, embryonic stem cells are the type of stem cells that generate the controversy most people associate with the topic.

Stem cell therapy has been around since the 1970s, when the first adult bone marrow cells were used to treat blood disease. A bone marrow transplant allows a recipient whose bone marrow cells have been damaged by chemotherapy or disease to receive healthy bone marrow stem cells from a donor.

Those stem cells have the potential to mature within the blood system into different immune cells that recognize and fight off different types of blood cancer. And they also have the ability to heal, says Betty Hamilton, MD, Department of Hematology and Medical Oncology.

Bone marrow transplants are currently used to treat diseases including:

While you may have heard about the use of stem cell therapy for knees, back pain, arthritis, hair loss, diabetes and more, no other types of stem cell therapy beyond bone marrow transplants have yet been approved by the FDA. But thousands of clinical trials are available ranging from treatments for Crohns disease to multiple sclerosis and more. The common link between all these trials is the ability of the stem cells to reduce inflammation and repair damage to your body.

Dr. Hamilton and Dr. Lightner agree that were only just beginning to scratch the surface of stem cell therapy. In recent years, during the height of the COVID-19 pandemic, many clinical trials were underway to explore whether stem cells could be used to help treat the damaged lungs in people severely affected by the disease.

I think potential is the perfect word to describe stem cells, says Dr. Hamilton. We know they have these anti-inflammatory and regenerative properties where they can provide a significant improvement to someone suffering from a certain disease. There are so many diseases where inflammation happens, and something needs to be repaired, and so any help the immune system can get provides a lot of potential.

Scientists are also researching whether adult stem cells can turn into pluripotent stem cells, which would allow the cells to change into any cell type without involving the use of embryonic stem cells.

While the potential for stem cell therapy is great, doctors caution that were not quite there yet.

I always tell patients that ask about stem cell therapy clinics or traveling overseas for stem cell therapy treatment that if its not something that is a clinical trial with FDA oversight, then they have no real way of knowing whats being given to them, advises Dr. Lightner.

This means more harm can come than good if you dont know exactly whats being given to you. Or, in some cases, youre just spending thousands of dollars for what ends up being saline, Dr. Lightner says.

The best way to know that youre receiving sound medical treatment is to make sure the one youre considering is approved by the FDA on its Clinical Trials database.

Dr. Lightner cautions against treatments that sound too good to be true. While stem cell therapy has helped improve and save millions of lives, its best to know what exactly youre signing up for by seeking out a qualified medical provider offering an FDA-approved clinical trial.

More:
Is Stem Cell Therapy Right for You? - Health Essentials from Cleveland Clinic

What is the potential stem cell ‘cure’ for HIV/AIDS all about? | In Focus podcast – The Hindu

Dr Akhil C Banerjea speaks to us on the rare mutation that naturally blocks HIV from entering cells and does the mRNA platform, first used for a COVID-19 vaccine, offer hope. Dr Akhil C Banerjea speaks to us on the rare mutation that naturally blocks HIV from entering cells and does the mRNA platform, first used for a COVID-19 vaccine, offer hope.

Up until January this year, only two people were ever reported cured of HIV/AIDS. And now, researchers have said there may be a third case -- an African American woman, who was diagnosed with HIV in 2013, and started on anti-retroviral therapy. In 2017, she was diagnosed with leukemia and received embryonic stem cells, in the form of cord blood, from a donor who had a rare mutation that naturally blocks HIV from infecting the bodys cells. She also received adult blood stem cells from a relative. Now, doctors say, the woman shows no signs of HIV in her blood and has no detectable antibodies either, making the 60-year-old woman possibly the third case of a person who has been cured of the virus -- the other two cases, both men, received bone marrow transplants as well, from donors with the rare mutation. Unlike the other two cases, however, the woman did not develop graft vs host disease -- a condition where the donor stem cells attack the recipient. Could this be because of the use of embryonic stem cells with adult stem cells? Her doctors believe this may possibly be a factor.

Stem cell therapy, exciting as it is in the field of medicine, is not accessible or possible in the case of a vast majority of persons living with HIV/AIDS in the world. Anti-retroviral therapy or ART however, has ensured that those with access to the medicines now have long lifespans, comparable to those without HIV/AIDS. A vaccine against the virus would be an ideal solution, offering a potential cure, but close to 40 years since researchers first began to study it, the world still does not have a vaccine for this virus, though there are recent reports of a potential vaccine based on the mRNA platform.

In India, as of 2019, an estimated 23.48 lakh people live with HIV/AIDS -- the prevalence among adult males is estimated at 0.24% of the population and among adult females, the prevalence is 0.20%. Worldwide, over 37 million people live with HIV/AIDS.

So what is the potential stem cell cure all about? What is the rare mutation that naturally blocks HIV from entering cells? Why is a vaccine so hard to make, and does the mRNA platform, first used for a COVID-19 vaccine, offer hope?

Guest: Dr Akhil C Banerjea, emeritus professor, National Institute of Immunology and former director, Institute of Advanced Virology, Kerala

Host: Zubeda Hamid

Edited by Reenu Cyriac

Go here to see the original:
What is the potential stem cell 'cure' for HIV/AIDS all about? | In Focus podcast - The Hindu

Stem cell therapy shows promise in aiding equine wound healing – Horsetalk.co.nz – Horsetalk

WCVM PhD student Dr Suzanne Mund. Rigel Smith

A team of researchers at the Western College of Veterinary Medicine (WCVM) in Saskatchewan has published the first equine study to demonstrate changes in wound healing following stem cell therapy.

The findings of the study, which received funding from the Mark and Pat DuMont Equine Orthopedic Fund and the WCVMs Townsend Equine Health Research Fund (TEHRF), were recently published online in Cells, an international open-access journal.

Team members include PhD student Dr Suzanne Mund along with WCVM faculty members Drs Daniel MacPhee, John Campbell, Ali Honaramooz, Bruce Wobeser and Spencer Barber.

The Canadian researchers used intravenous (IV) treatments of multipotent mesenchymal stromal cells (MSCs) that were extracted from other horses. These stem cells have potential for improving wound healing because they can alter the bodys inflammatory response, which is involved in healing. They can also influence other local cells to produce growth factors that could enhance the speed and quality of wound healing.

MSC therapy is a promising treatment for limb wounds, a common injury in horses that often develops complications, which can include the production of an excess amount of granulation tissue, commonly known as proud flesh.

There are risks associated with IV administration of MSC, and so far, the therapys effectiveness in improving cutaneous wound healing is unknown.

The WCVM research team was successful in administering the highest dose of MSCs ever administered to horses enrolled in the study (using any type of delivery). Contrary to the teams hypothesis, the treated horses did not experience accelerated wound closure or improved histologic healing. However, the horses healed wounds did have smaller immature scar sizes, which may signal a better repair in terms of cosmetics and function.

The stem cell therapy also appeared to alter the cytokine profile within the horses wounds. Cytokines are small proteins that play a role in controlling the growth and activity of other immune system cells and blood cells. After treatment, there was less expression of all measured cytokine types except for antifibrotic mediators.

This finding is contrary to researchers understanding that more acute inflammation followed by rapid resolution improves limb wound healing.

Another concern was that several of the horses in the treatment group temporarily developed minor reactions after receiving stem cell therapy. Since one horse in the control group also experienced similar transient reactions, the cause may be related to the cell suspension solution used or to other external factors rather than to the cells themselves.

While MSC intravenous therapy has the potential to decrease the size of limb wounds in horses, researchers need to do further studies before this therapy can be recommended as an effective wound healing tool for veterinarians in the field. More work also needs to be done to understand the clinical relevance of adverse reactions that were observed in the studys horses.

Reprinted with permission from the Western College of Veterinary Medicines Townsend Equine Health Research Fund.

See original here:
Stem cell therapy shows promise in aiding equine wound healing - Horsetalk.co.nz - Horsetalk

Early Treatment Matters More Than Ever in Multiple Myeloma, Kumar Says – AJMC.com Managed Markets Network

Whether a patient is refractory to initial treatment dictates the future course of care.

The multitude of options to treat multiple myeloma (MM) doesnt change an important fact: the duration of a patients response to the first treatment will define the disease biology going forwardhow well the disease is managed in the early going matters, according to Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, who gave an update on MM management during Fridays National Comprehensive Cancer Center (NCCN) annual meeting.

Fortunately, results from the GRIFFIN trial are showing whats possible. Results presented at the December 2021 meeting of the American Society of Hematology showed positive outcomes after 24 months for newly patients who took quadruplet therapy after an autologous stem cell transplant (ASCT). The combination, which added daratumumab to the usual combination of lenalidomide, bortezomib, and dexamethasone (RVd) had better stringent complete responses (sCR, 66.0% vs 47.4%), along with higher minimal residual disease (MRD) negativity rates.

This clearly appears to be translating into an improvement in progression-free survival (PFS), Kumar said. Its too soon to start treating every patient with newly diagnosed, transplant-eligible MM this way, but given the high rates of MRD negativity that we see with Dara-RVd, this regimen is definitely one to consider for patients with high risk multiple myeloma.

What about patients who are not transplant eligible, or need to wait? The IFM 2009 study compared giving ASCT right away with additional doses of therapy. Although ASCT clearly offered better PFS, there was not improvement in overall survival (OS), Kumar noted. Thus, it is very reasonable to delay stem cell transplant to the time of first relapse.

For these patients, daratumumab with lenalidomide and dexamethasone should be considered the standard, based on the MAIA study, he said.

Ongoing treatment. After initial treatment and lenalidomide maintenance, treatment choices are driven by whether patients are refractory to lenalidomide, Kumar explained. He shared a slide with multiple doublet and triplet options, and explained that triplets are now preferred, with one drug being dexamethasone. Prior treatments, age, comorbidities, frailty, and any lingering toxicity should be considered.

In general, the approachespecially in the earlier lines of therapyis to treat patients to maximum response, and then maintain them on at least one of the drugs from the combination until disease progression, Kumar said. This is easier in the early lines of therapy, he acknowledged. Whether a patient is refractory on their initial therapy is a key differentiator is a key differentiator that guides treatment going forward.

Selinexor, an XP01 inhibitor, was approved in December 2020 for use with bortezomib and dexamethasone in patients who have had at least one prior therapy. Belantamab mafodotin, is an antibody drug conjugate that targets B-cell maturation antigen (BCMA), and could be used to treating patients that have been refractory to other major drug classes, including protease inhibitors. Long-term data from the DREAMM-2 study found that median duration of response, OS, and PFS were 11.0 month, 13.7 months, and 2.8 months.

A recent highlight is the FDA approval last month of a second chimeric antigen receptor (CAR) T-cell therapy for MM, ciltacabtagene autoleucel (cilta-cel) which also targets BCMA. In the CARTITUDE trial, results at 2 years showed median PFS and OS were not reached and sCR was 82.5%.

Kumar also reported on several clinical trials involving investigational therapies and new uses of existing therapies, including:

Read more:
Early Treatment Matters More Than Ever in Multiple Myeloma, Kumar Says - AJMC.com Managed Markets Network